Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs.
Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk."
With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015.
At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema.
"Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal."
What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities.
To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo.
Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says.
While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties.
What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way."
With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare.
Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it."
The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency.
For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community."
As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
2 hours ago
- Int'l Business Times
Sahel Juntas Pile Pressure On Foreign Mining Firms
Army strongmen who have seized power in coups across Africa's Sahel region since 2020 have ramped up pressure on foreign mining companies in the name of greater control over their countries' riches. Niger's nationalisation of the local branch of French uranium giant Orano on Thursday is the latest such measure by the junta and its allies in Burkina Faso and Mali. In particular the coup-hit trio, which have all turned their backs on their shared former colonial master France in favour of stronger ties with Russia, have placed Western firms firmly in their sights. Niger's nationalisation of Orano's local branch Somair has brought a months-long struggle with the French firm to a peak. Orano, which is 90-percent owned by the French state, had already admitted to having lost operational control of its subsidiary months ago. Meanwhile in Mali, Canadian giant Barrick Mining is locked in a tug-of-war with the army over a mining code that came into force in 2023. The military is demanding hundreds of millions of dollars of back taxes from the firm. Barrick has since lost control of Loulo-Gounkoto, the country's largest gold mine, in which the Canadian firm holds a majority stake. In November 2024, Malian soldiers arrested the director of Australia's Resolute Mining, along with two employees. All were subsequently released after Resolute agreed to pay the junta $160 million in exchange. Other mine companies such as Canada's allied Gold, B2Gold and Robex had previously agreed to review their activities and pay to settle their tax or customs dispute. And in 2023 Burkina Faso seized 200 kilograms (440 pounds) of gold produced by a branch of Canada's Endeavour Mining on "public necessity" grounds. For the juntas, the point of the push against foreign mining companies is to reestablish sovereignty and control over their national resources. Where they believed the Sahel's resource riches were previously sold out to foreigners, and to the West in particular, today the army leaders promise their people that ordinary citizen will receive a greater share of the profits from the wealth under their feet. Niger produces nearly five percent of the world's uranium. Gold makes up a quarter of Mali's national budget. And Burkina Faso's gold production contributes around 14 percent of the country's revenues, according to official statistics. "The population sees this as a push to free states which were previously, according to the new authorities, subservient to Westerners and therefore foreign interests," said Jeremie Taieb, director of consulting firm Tikva Partners. This rejection therefore "helps to satisfy public opinion and nurtures a narrative that allows those in power to keep it", Taieb added. All three countries are plagued by jihadist violence, which has claimed thousands of lives across the region. Besides economic sanctions imposed on the juntas in the wake of the coups, "the pressures exerted to fund the fight against terrorism" provide as good a reason as any "to extract more income from the sector", said Beverly Ochieng, an analyst at Control Risks. To fight back against the juntas, the mining industry has looked to international arbitration. Barrick has turned to the International Centre for Settlement of Investment Disputes (ICSID), part of the Washington-based World Bank. France's Orano has launched various lawsuits against the state of Niger, accusing the junta of a "systematic policy of stripping mining assets". In a statement Friday evening, the day after Niger announced its intention to nationalise its subsidiary, the firm said it "intends to claim compensation for all of its damages and assert its rights over the stock corresponding to Somair's production to date". For Taieb, this "legal instability" in the Sahel could drive investors towards countries with a more reliable business backdrop. But for Control Risks' Ochieng, "foreign firms will probably continue to engage with administrations in the Sahel... as mining assets represent a hefty and long-term investment". In any case the countries that stand to gain most from the current climate are Mali, Niger and Burkina Faso's so-called "security partners" -- especially Turkey, China and Russia. On Monday, Mali and Russia began construction work on a new gold refinery in the Malian capital Bamako. Moscow has also sent mercenaries from its paramilitary Africa Corps to the Sahel country to help fight jihadists. For the Russians, the deal is "minerals for weapons, in the same way that for the Chinese, it's minerals for infrastructure", said Taieb.
Int'l Business Times
a day ago
- Int'l Business Times
ITBIOMETRICS™ Unveils the DOGOOD™ Card Transforming Financial Security and Merchant Savings
ITBIOMETRICS™, a trailblazer in capacitive biometric authentication, is set to revolutionize the cryptocurrency and credit card landscape with its latest innovation, the DOGOOD™ card. This product promises to offer far-reaching benefits to both consumers and card merchants, delivering enhanced security and significant cost savings. It also allows for instantaneous logging in and purchasing of merchandise without passwords, account numbers, and multi-factor authentication and CAPTCHA by substituting biometrics. For cryptocurrency users, not only does it prevent losses from hacking but also from failed cryptocurrency exchanges by making cryptocurrency ownership far simpler and more secure. It's simpler because there are no 64-character passphrases to remember, and if the user ever loses their ITBx™ cryptocurrency wallet, all they need to do is obtain another wallet, and all of the digital assets they own will reappear. The invention uses the fingerprint itself to encrypt and decrypt information. Financial transactions are becoming increasingly vulnerable to hacking, including the cryptocurrency market. The result is a financial ecosystem plagued by billions of dollars in losses by card merchants, customers, and cryptocurrency enthusiasts due to fraud and identity theft. According to Howard Prager , CEO of ITBIOMETRICS™, merchants grapple with a significant percentage of holdback and high card fraud loss chargebacks. ITBIOMETRICS™ recognized these critical pain points and developed the DOGOOD™ card to address them head-on. The DOGOOD™ card utilizes simultaneously four factors and a fingerprint substitute for the user's password. It ensures that only the rightful owner can authorize transactions. By incorporating four types of biometric sensors, the card verifies the user's identity through fingerprint recognition and a method far more secure than traditional passwords by capturing infrared pictures of the finger flesh. The only thing that the user has to remember is which fingers to use. "This approach can drastically reduce the risk of fraud and hacking," says Prager. This offers unprecedented protection against unauthorized access. Moreover, the DOGOOD™ card integrates seamlessly with major payment card brands, ensuring widespread acceptance and convenience for users. Consumers could benefit from enhanced security and peace of mind. It is important to note that the fingerprint never leaves the device. Whatever is sent to credit card merchants and banks, and cryptocurrency exchanges and currencies, are highly encrypted signals. It eliminates the need for remembering complex passwords or PINs, offering a more convenient and secure user experience in seconds. The DOGOOD™ card also provides an optional rebate system, where users accumulate savings throughout the year, which can be distributed on their account anniversary. "Since the DOGOOD™ card can prevent identity theft and credit card fraud, one of the major card brands estimates that banks can save a significant percentage of their credit card overhead. They can compete with one another for new customers by offering increasingly larger rebates. The reason is that they want to capture debit, as well as credit card business, as they make a profit on each transaction. Some may reduce interest rates on credit cards to compete with consumers who are more sensitive to interest rates," shares Prager. These rebates can be directed towards personal savings, charitable donations, or tips to companies that have provided exceptional service, creating a culture of generosity and community support. Howard further expresses, "We have created this service for our clients so that they could act like a 'Santa Claus' at least once each year, spreading joy to recipients all year round." "To understand the scale of the beneficial effects on the economy, major payment platforms collectively earn trillions of dollars a year. It is likely that the typical card merchant will save a significant percentage of their chargebacks. The arithmetic tells us that card merchants collectively can have substantial profits when the DOGOOD™ card becomes ubiquitous," says Prager. In addition to its financial security benefits, the DOGOOD™ card introduces innovative features to protect users in critical moments. DOGOOD™ is equipped with an AI named SHREEDAAN. That name means 'do good' in Hindi. The integration system provides users with a guardian angel-like AI service. This system appears with a humanlike image with facial recognition and location tracking to identify and respond to potential threats, activating emergency protocols to safeguard the user when using their Panic Finger established during setup. With necessary certifications like FIDO2 (Fast Id Online), ITBIOMETRICS™ continues to advance its technology. Media Contact Name: Howard Prager Email: hprager@
Int'l Business Times
2 days ago
- Int'l Business Times
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs. Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk." With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015. At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema. "Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal." What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities. To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo. Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says. While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties. What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way." With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare. Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it." The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency. For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community." As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
